Spelling suggestions: "subject:"lentivectors"" "subject:"lentiviraler""
1 |
Construction of Lentivirus Vectors for Modulating Intrinsic Dendritic Cell PropertiesWang, James Chian-Ming 30 December 2010 (has links)
Dendritic cells (DCs) are promising mediators of anti-tumour immune responses. Unfortunately, a major hindrance to the development of highly effective DC vaccines is their short lifespan. Tumour antigen presentation may also not be optimal. We hypothesize that the introduction of exogenous survival factors (SFs) would prolong DC longevity and that modulation of TAA glycosylation will improve antigen presentation. To this end, we have constructed bicistronic lentivectors (LVs) encoding the xeno Tumour-Associated-Antigen (TAA), rHER-2/neu, and one of five candidate SFs. We demonstrated that our LVs can effectively protect transduced DCs from apoptosis when subjected to apoptosis-inducing conditions. TAA glycosylation has been proposed to obstruct the processing and presentation of peptides on MHC molecules. To address this second issue, we have engineered a LV that encodes a partially deglycosylated rHER-2/neu. Overall, we have generated the tools to alter intrinsic DC properties, which we believe will be integral to improving DC vaccine efficacy.
|
2 |
Construction of Lentivirus Vectors for Modulating Intrinsic Dendritic Cell PropertiesWang, James Chian-Ming 30 December 2010 (has links)
Dendritic cells (DCs) are promising mediators of anti-tumour immune responses. Unfortunately, a major hindrance to the development of highly effective DC vaccines is their short lifespan. Tumour antigen presentation may also not be optimal. We hypothesize that the introduction of exogenous survival factors (SFs) would prolong DC longevity and that modulation of TAA glycosylation will improve antigen presentation. To this end, we have constructed bicistronic lentivectors (LVs) encoding the xeno Tumour-Associated-Antigen (TAA), rHER-2/neu, and one of five candidate SFs. We demonstrated that our LVs can effectively protect transduced DCs from apoptosis when subjected to apoptosis-inducing conditions. TAA glycosylation has been proposed to obstruct the processing and presentation of peptides on MHC molecules. To address this second issue, we have engineered a LV that encodes a partially deglycosylated rHER-2/neu. Overall, we have generated the tools to alter intrinsic DC properties, which we believe will be integral to improving DC vaccine efficacy.
|
3 |
Distribution cellulaire de la protéine de la nucléocapside NCp7 du VIH-1 et caractérisation de son interaction avec la protéine nucléolaire hNoL12 / Cellular distribution of the nucleocapsid protein of HIV-1 NCp7 and characterization of its interaction with the nucleolar protein hNoL 12Zgheib, Sarwat 08 December 2015 (has links)
La protéine de nucléocapside (NC) du virus de l’immunodéficience humaine (VIH-1) joue un rôle majeur dans les différentes étapes du cycle viral du VIH-1 : soit comme domaine fonctionnel de la polyprotéine Gag (NC-Gag) dans les phases tardives du cycle viral, soit sous sa forme mature NCp7 dans les phases précoces. Afin de mieux comprendre le rôle de la forme mature dans le cycle viral, nous avons cherché de nouveaux partenaires cellulaires spécifiques de la NCp7 et identifié la protéine nucléolaire, hNoL12, impliquée dans la maturation des ARNs ribosomaux. L’interaction NCp7/hNoL12 a été confirmée par co-IP, FRET-FLIM et double hybride chez la levure et le domaine d’interaction a été localisé entre les a.a. 22 et 61 correspondant au domaine 5’-3’-exonucléase de hNoL12. Nous avons développé un test pour caractériser cette activité et montré qu’elle est spécifique des ARN simples brins. Enfin, l’extinction de l’expression de hNoL12 entraine une diminution significative de l’infection par un lentivecteur modèle des phases précoces de l’infection soulignant l’implication fonctionnelle de hNoL12 dans cette phase de l’infection. Dans un second projet, nous nous sommes intéressés au devenir de la NCp7 dans les cellules infectées, suite à la transcription inverse. Nous avons généré des vecteurs lentiviraux composés de protéines NCp7 fusionnées à une étiquette tétracysteine permettant son marquage spécifique avec le dérivé de la fluorescéine (FlAsH). Nous avons alors étudié, par microscopie confocale, la distribution intracellulaire de la NCp7 dans des conditions proches de l’infection. Nos résultats indiquent qu’une grande partie de la NCp7 se dissocie du PIC durant son transport dans le cytoplasme. Toutefois, la perte de la NCp7 est une étape tardive qui se déroule proche du noyau confirmant ainsi que la décapsidation a lieu à la membrane nucleaire juste avant l’entrée du complexe de préintegration dans le noyau. Le troisième projet a porté sur le développement d’antiviraux ciblant la NCp7. Nous avons travaillé sur la vectorisation et la caractérisation des propriétés antivirales en milieu cellulaire, d’un peptide sélectionné in vitro pour sa capacité à inhiber l’action chaperonne de la NCp7. L’activité antivirale du peptide vectorisé vis-à-vis d’une infection par un vecteur lentiviral basé sur le VIH-1 s’est révélée décevante. / The Human Immunodeficiency Virus-1 (HIV-1) nucleocapsid protein (NC) plays a major role in the different steps of theviral lifecycle under its two forms; either as a domain of the polyprotein Gag (NC-Gag) in the late phase or as a matureNCp7 protein in the early phase. In order to better understand the role of the mature form in the viral cycle, we searchedfor new NCp7 specific cellular partners and identified the nucleolar protein hNoL12 which is known to be involved inthe maturation of ribosomal RNAs. The NCp7/hNoL12 interaction was confirmed by co- IP, FRET-FLIM, and yeast twohybrid. The interaction domain was localized between a.a. 22 and 61 on hNoL12; which corresponds to its putative 5’-3’-exonuclease domain. We developed an assay to monitor this activity and found it to be specific of single strand RNA.Finally, the cellular knockdown of hNoL12 resulted in a significant decrease in the infection by a pseudovirus mimickingthe early phase of the infection, emphasizing the functional involvement of hNoL12 in this phase. In a second project, wewere interested in the fate of the viral incoming NCp7 in the infected cells, after reverse transcription. We thus generatedlentiviral vectors composed of NCp7 fused to a tetracysteine tag enabling its specific labeling with the fluoresceinderivative FlAsH. We then studied by confocal microscopy, the intracellular distribution of NCp7 containing viralparticles in conditions close to the infection. Our results showed that an important proportion of the NCp7 moleculesdissociates from the PIC during its transport in the cytoplasm. However, the loss of NCp7 is a late step of this processand seems to take place close to the nucleus suggesting that the dissociation of the capsid occurs at the nuclear membranejust before the nuclear entry of the PIC. The third project concerns the development of antiviral inhibitors targetingNCp7. We worked on the vectorization and the characterization of the antiviral properties of a peptide selected in vitrofor its ability to inhibit the NCp7 chaperone activity. The inhibitory activity of the vectorized peptide on infection ofHeLa cells by a HIV-1 based lentiviral vector was found deceiving.
|
Page generated in 0.0786 seconds